Dr. Lal PathLabs Limited

As of March 31, 2026, Dr. Lal PathLabs Limited carries a market capitalization of 219.39B, placing it among publicly traded companies globally. Its enterprise value stands at 208.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dr. Lal PathLabs Limited's next confirmed earnings release is scheduled for November 4, 2026.

As of March 31, 2026, Dr. Lal PathLabs Limited has 166.98M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Dr. Lal PathLabs Limited maintains a current ratio of 3.48, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Dr. Lal PathLabs Limited recorded 1.08B in income tax expense.

As of the close on October 23, 2026, Dr. Lal PathLabs Limited's stock has gained approximately 19.74% over the past 52 weeks. The 50-day moving average sits at 1,915.91, while the 200-day moving average is 1,626.41.

As of March 31, 2026, Dr. Lal PathLabs Limited holds 13.31B in cash and equivalents against 1.99B in total debt, resulting in a net debt position of -2.43B. Total book value stands at 25.08B, with working capital of 11.16B providing operational flexibility.

Dr. Lal PathLabs Limited's most recent stock split took place on December 19, 2025 with a 1:2 split ratio.